Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progre...

Full description

Bibliographic Details
Main Authors: Kathrin Oehl, Jelena Kresoja-Rakic, Isabelle Opitz, Bart Vrugt, Walter Weder, Rolf Stahel, Peter Wild, Emanuela Felley-Bosco
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-02-01
Series:Frontiers in Oncology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fonc.2018.00040/full
id doaj-59dee1ae4adf4cf98b6d3cd5f9a10a23
record_format Article
spelling doaj-59dee1ae4adf4cf98b6d3cd5f9a10a232020-11-24T22:41:56ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2018-02-01810.3389/fonc.2018.00040319846Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor ProgressionKathrin Oehl0Jelena Kresoja-Rakic1Isabelle Opitz2Bart Vrugt3Walter Weder4Rolf Stahel5Peter Wild6Emanuela Felley-Bosco7Department of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, SwitzerlandLaboratory of Molecular Oncology, Division of Thoracic Surgery, University Hospital Zürich, Zürich, SwitzerlandLaboratory of Molecular Oncology, Division of Thoracic Surgery, University Hospital Zürich, Zürich, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, SwitzerlandLaboratory of Molecular Oncology, Division of Thoracic Surgery, University Hospital Zürich, Zürich, SwitzerlandCancer Center Zürich, University Hospital Zürich, Zürich, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, SwitzerlandLaboratory of Molecular Oncology, Division of Thoracic Surgery, University Hospital Zürich, Zürich, SwitzerlandExperimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can be obtained in vitro, providing a useful tool to investigate underlying mechanisms. Primary mesothelioma cultures were established from 235 samples between 2007 and 2014. Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated. Cells and corresponding tumor tissue were characterized by mesothelial protein and gene expression analysis. In addition, primary cultures from chemo naive patients were exposed to increasing doses of cisplatin/pemetrexed during three months and compared with non-treated cells in a cytotoxicity assay, and by selected profiling of senescence markers. In vitro chemoresistance in the primary mesothelioma cell cultures was associated with increased Thy1 (CD90) expression. Thy1 expression in MPM samples was significantly associated with poor overall survival in the TCGA MPM cohort. Our results illustrate that the establishment of a large live-cell MPM biobank contributes to a better understanding of therapy resistance observed in vivo, which eventually may lead to a more logical approach for developing new treatment strategies.http://journal.frontiersin.org/article/10.3389/fonc.2018.00040/fullmesotheliomaprimary culturetumor progressionchemoresistancegenetic profilingmutations
collection DOAJ
language English
format Article
sources DOAJ
author Kathrin Oehl
Jelena Kresoja-Rakic
Isabelle Opitz
Bart Vrugt
Walter Weder
Rolf Stahel
Peter Wild
Emanuela Felley-Bosco
spellingShingle Kathrin Oehl
Jelena Kresoja-Rakic
Isabelle Opitz
Bart Vrugt
Walter Weder
Rolf Stahel
Peter Wild
Emanuela Felley-Bosco
Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
Frontiers in Oncology
mesothelioma
primary culture
tumor progression
chemoresistance
genetic profiling
mutations
author_facet Kathrin Oehl
Jelena Kresoja-Rakic
Isabelle Opitz
Bart Vrugt
Walter Weder
Rolf Stahel
Peter Wild
Emanuela Felley-Bosco
author_sort Kathrin Oehl
title Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title_short Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title_full Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title_fullStr Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title_full_unstemmed Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title_sort live-cell mesothelioma biobank to explore mechanisms of tumor progression
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2018-02-01
description Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can be obtained in vitro, providing a useful tool to investigate underlying mechanisms. Primary mesothelioma cultures were established from 235 samples between 2007 and 2014. Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated. Cells and corresponding tumor tissue were characterized by mesothelial protein and gene expression analysis. In addition, primary cultures from chemo naive patients were exposed to increasing doses of cisplatin/pemetrexed during three months and compared with non-treated cells in a cytotoxicity assay, and by selected profiling of senescence markers. In vitro chemoresistance in the primary mesothelioma cell cultures was associated with increased Thy1 (CD90) expression. Thy1 expression in MPM samples was significantly associated with poor overall survival in the TCGA MPM cohort. Our results illustrate that the establishment of a large live-cell MPM biobank contributes to a better understanding of therapy resistance observed in vivo, which eventually may lead to a more logical approach for developing new treatment strategies.
topic mesothelioma
primary culture
tumor progression
chemoresistance
genetic profiling
mutations
url http://journal.frontiersin.org/article/10.3389/fonc.2018.00040/full
work_keys_str_mv AT kathrinoehl livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT jelenakresojarakic livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT isabelleopitz livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT bartvrugt livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT walterweder livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT rolfstahel livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT peterwild livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT emanuelafelleybosco livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
_version_ 1725700096887095296